Ani Pharmaceuticals Inc (ANIP)
R&D Expense Growth
39.12%
Quarterly · Period ending:
ANIP R&D Expense Growth
Latest reported39.12%period ending
Latest reported39.12%period ending
ANIP Quarterly R&D Growth (QoQ) (0.00% → 39.12%)
Latest values, visible window
High-resolution chart · PNG
ANIP r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 39.1226% | |
| -13.547% | |
| -0.3495% | |
| -25.5881% | |
| 56.5222% | |
| -36.5373% | |
| 64.3562% | |
| 38.8158% | |
| -30.587% | |
| 6.5268% | |
| -11.276% | |
| 50.8137% | |
| 24.4767% | |
| 13.4431% | |
| -31.801% | |
| 83.8415% | |
| -21.0277% | |
| 67.9618% | |
| 27.8502% | |
| -12.4421% | |
| -5.4919% | |
| -19.4135% | |
| 25.3147% | |
| -3.1631% | |
| -52.1595% | |
| 35.6135% | |
| -6.102% | |
| -13.7017% | |
| 32.0146% | |
| 25.5887% | |
| -25.391% | |
| -9.1493% | |
| 144.3863% | |
| -20.7092% | |
| 0.6454% | |
| 21.5505% | |
| 33.9308% | |
| 1,098.5185% | |
| -87.0317% | |
| 36.2565% | |
| -20.911% | |
| 46.1422% | |
| -18.8957% | |
| -18.0905% | |
| 146.8983% | |
| -29.0493% | |
| -35.6738% | |
| 3.7603% | |
| 126.3298% | |
| -28.2443% | |
| 15.4447% | |
| 3.8229% | |
| -55.0245% | |
| -60.0734% | |
| -37.1351% | |
| -28.2601% | |
| 4.1497% | |
| -22.6546% | |
| -41.7273% | |
| 3.452% | |
| -25.2152% | |
| 24.8593% | |
| 22.528% | |
| 12.2261% | |
| -8.1603% | |
| 151.817% | |
| 11.0442% | |
| -3.5024% | |
| 13.7143% | |
| -20.3142% | |
| -27.5629% | |
| 35.2901% | |
| 46.908% | |
| 120.9104% | |
| 5.8012% | |
| -14.9624% | |
| 47.4376% | |
| -4.3691% | |
| 24.656% | |
| -31.2219% | |
| 9.3938% | |
| 0.3594% | |
| -22.7542% | |
| -31.8279% | |
| -10.4007% | |
| -36.5227% | |
| 38.3269% | |
| 31.3406% | |
| 28.0961% | |
| 47.2815% | |
| 2.9924% | |
| 2.2448% | |
| 16.9297% | |
| -56.072% | |
| 37.8261% | |
| 34.331% | |
| 53.2491% | |
| -19.7104% | |
| 11.605% | |
| 85.709% |